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Introduction
Pneumonia is the leading single cause of mortality in children
aged less than 5 years with approximately 1.6 million children
dying each year [1]. This accounts for almost one in five under-5
deaths worldwide. Furthermore, approximately 155 million new
episodes of clinical pneumonia occur in children under 5 years of
age annually [2]. It is estimated that 7%–13% of episodes are
severe enough to be life-threatening and require hospitalisation
[3]. Studies have identified Streptococcus pneumoniae, Haemophilus
influenzae, and respiratory syncytial virus (RSV) as the main
pathogens associated with severe childhood pneumonia [4–6].
Future studies, with new molecular techniques to detect infections
due to a wider range of pathogens, will improve our understanding
of the cause of pneumonia [7]. The leading risk factors
contributing to pneumonia incidence are lack of exclusive
breastfeeding, undernutrition, exposure to indoor air pollution,
low birth weight, crowding, and absence of immunisation [3].
Initiatives to Control Childhood Pneumonia
The United Nation’s (UN) Millennium Development Goal 4
(MDG4) states that childhood mortality should be reduced by two-
thirds between 1990 and 2015, but recent estimates show that the
progress in mortality reduction has been disappointing in some
countries [8,9]. Key reasons are lack of knowledge on how to
implement existing cost-effective interventions and to achieve greater
coverage of these interventions in low-resource settings [10], and the
need to develop new effective interventions to amplify case
management and immunisation strategies. In an attempt to accelerate
progress in tackling childhood pneumonia, two major initiatives have
been taken. A Global Action Plan for the Prevention and Control of
Pneumonia (GAPP) was launched late in 2009 by the World Health
Organization (WHO) andUNICEF in collaboration with other global
partners, with a multitude of aims and several ongoing activities (see
Box 1) [11]. The secondmajor initiative was the successful passage of a
resolution on the prevention and control of childhood pneumonia at
the 2010 World Health Assembly. The resolution calls on the WHO
to strengthen human resources in tackling this problem and to create
an international forum to coordinate action. It calls on WHO
Member States to create evidence-based and multi-sectoral action
plans and to monitor progress [12].
Mismatch of Pneumonia Mortality Burden and
Research Investment
The positive initiatives need research and investment, but neither
has been commensurate with the importance of pneumonia as the
leading child killer [13]. It has been shown that the amount of
available research funds per disability-adjusted life year (DALY) of
pneumonia is orders of magnitude lower compared to many other
diseases today [14,15]. To assist policy-makers and donors alike in
understanding the potential of different research avenues to contribute
to reducing the burden of disease and disability, the Child Health and
Nutrition Research Initiative (CHNRI) recently developed a
methodology that allows systematic listing and transparent scoring
of many competing research options, thus exposing their strengths and
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weaknesses [16–18]. TheDepartment of Child and Adolescent Health
and Development (CAH) of WHO has used this methodology to
identify health research priorities to tackle all the major causes of child
deaths, and some of the exercises have already been published [19–
21]. In this paper, we present the results of the CHNRI research
priority-setting process for childhood pneumonia.
Methods
The CHNRI methodology for setting priorities in health
research investments was proposed to inform those who develop
research policy and/or invest in health research [16–18]. This
aims to assist policy makers to understand the full spectrum of
research investment options and the potential risks and benefits
that can result from investments in different research. As shown in
the published CONSORT diagram [13], the CHNRI methodol-
ogy has four stages: (i) input from investors/policy-makers (who
define the context and the criteria for priority setting); (ii) input
from a larger group of technical experts (who propose, list
systematically, and then independently score many research ideas);
(iii) input from other stakeholders (who agree on differential
weights for the chosen priority-setting criteria according to a wider
societal system of values) [16–18,22]; and (iv) computation and
discussion of the scores and analysis of the agreement between
experts. The conceptual framework for the CHNRI methodology
is shown in Figure 1. More detailed explanation has been
published elsewhere [16–18,22] and is also available in Table S1.
(i) Input from Investors/Policy-Makers
The WHO CAH programme coordinated a large international
exercise, involving more than 200 experts from about 80 different
countries, to identify health research priorities that could directly
tackle the main causes of global child mortality. The aim was to
inform key global donors, public investors in health research, and
international agencies on research investment policies that could
support efforts to accelerate the progress towards MDG4. Thus,
the context for this exercise was a short-term one, set within
MDG4 and requiring an urgent and rapid progress in mortality
reduction from childhood pneumonia. While defining this context,
the WHO also recognised the importance of context-specific issues
at local or regional levels, the large problem of pneumonia
morbidity, and the beneficial effects of investments in the
improvement of malnutrition and other cross-cutting and cross-
sectoral issues [17,18]. Further details are provided in Table S1.
(ii) Input from Technical Experts
Individuals with a wide range of technical expertise and regional
representation were recruited to participate. A large list of research
questions was drafted by the technical expert group based on recent
systematic reviews and a survey of experts. Initially, more than 500
questions were proposed. They were organised using the CHNRI
framework for listing research questions, shown in Table S2. They
were then compressed into a smaller number (158 questions) that still
represented the broad spectrum of health research areas, topics, and
instruments. The expert group then reviewed the questions, refining
and reformulating them to allow the scoring. The final questions were
sent to each technical group member for scoring. The criteria that
were adopted were: (i) answerability (which captures the likelihood
that each proposed research question can indeed be answered through
a well designed study and in an ethical way, using the existing level of
research capacity); (ii) likelihood of effectiveness; (iii) likelihood of
deliverability, affordability, and sustainability; (iv) maximum potential
impact on mortality reduction; and (v) predicted impact on equity.
The CHNRI framework for scoring research questions is shown in
Table S3 [17,18]. Further details are provided in Table S1.
(iii) Solicited Input from Other Societal Stakeholders
The five criteria for scoring may be perceived to be of
varying importance and the value given to each criterion may
vary with the perspective of stakeholders. For example, parents
Summary Points
N This paper aims to identify health research priorities that
could assist the rate of progress in childhood pneumonia
mortality reduction globally, as set out in the United
Nation’s Millennium Development Goal 4.
N The authors applied the Child Health and Nutrition
Research Initiative methodology for setting priorities in
health research investments. The process was coordi-
nated by the World Health Organization.
N Forty-five leading childhood pneumonia researchers
suggested more than 500 research ideas, which were
merged into 158 research questions that spanned the
broad spectrum of epidemiological research, health
policy and systems research, improvement of existing
interventions, and development of new interventions.
N Within the short time frame in which gains were
expected globally, the research priorities were dominat-
ed by health systems and policy research topics (e.g.,
studying barriers to health care seeking and access, as
well as barriers to increased coverage with available
vaccines; and evaluating the potential to safely scale up
antibiotic treatment through community health work-
ers).
N These were followed by epidemiological questions to
identify the main gaps in knowledge (e.g., predictors of
severe pneumonia that requires hospitalisation); priori-
ties for improvement of the existing interventions (e.g.,
training of community health workers to recognise
danger signs, refer, and treat sick children); and
identifying cost reduction mechanisms for the available
conjugate vaccines.
N Among the new interventions, the greatest support was
shown for the development of low-cost conjugate
vaccines and cross-protective common protein vaccines
against the pneumococcus.
Box 1. Global Action Plan for the Prevention
and Control of Pneumonia (GAPP)
GAPP aims to increase awareness of pneumonia as a major
cause of child death, calls for the scaling up of the use of
the interventions of proven benefit, and provides guidance
on how this can be done. The GAPP calls to action a broad
coalition of global and government policy-makers, donor
agencies, and civil society. GAPP recommends that every
child is protected against pneumonia through a healthy
environment, and has access to preventive and treatment
measures. The key GAPP strategies for treating, prevent-
ing, and protecting from pneumonia are case manage-
ment at all levels, vaccination, prevention and manage-
ment of HIV infection, improvement of nutrition and
breastfeeding, reduction of low birth weight, and control
of indoor air pollution. Furthermore, pneumonia is
recognised as a common and serious consequence of
pandemic influenza, and preparedness for pandemic
influenza should include prevention and control of
pneumonia [11].
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who have experienced a pneumonia-associated death may rate
mortality reduction much higher than a research funder who
may value answerability, or a health system planner who may
be most concerned with deliverability. Hence, CHNRI
undertook an exercise to poll a wide range of stakeholders
and to weight the criteria based on values assigned by these
stakeholders, as described elsewhere [22]. The weights applied
in this exercise are explained in detail in Table S1.
(iv) Computation of the ‘‘Research Priority Scores’’ and
Average Expert Agreement
Completed worksheets were returned to the group coordinator.
The overall research priority score (RPS) was computed as the mean
of the scores for the five criteria [18], weighted according to the input
from the stakeholders [22], according to the following formula:
RPS~
Criterion 1 score  0,96ð Þz Criterion 2 score  0:86ð Þz
Criterion 3 score  0,86ð Þ
z Criterion 4 score  1,75ð Þz Criterion 5 score  0,91ð Þ
0
BB@
1
CCA=5
Average expert agreement (AEA) scores were also computed for
each research question as the average proportion of scorers that
gave the most common answer while scoring that particular
research question. This is computed for each scored research
investment option as:
AEA average expert agreementð Þ~
1
15
|
X15
q~1
N scorers who provided the most frequent responceð Þ
N scorersð Þ
(where q is a question that experts are being asked to evaluate
competing research investment options, ranging from 1 to 15). For
further details regarding the choice of methods, agreement
statistics, and interpretation, see Table S1.
Results
Table 1 shows the top 10% of the 158 research questions, and
Table S4 shows the complete list of ranks and scores. Both tables
present the perceived likelihood that each research question
will comply with each of the five chosen priority-setting criteria.
Figure 1. CHNRI’s conceptual framework showing key steps required to get from investments in health research options to
decrease in burden of death, disease, or disability. The framework identifies criteria to discriminate between likelihoods of success of
competing research options: (i) answerability; (ii) effectiveness; (iii) deliverability; (iv) maximum potential for disease burden reduction; and (v)
predicted impact on equity in the population (right side). These criteria are not necessarily what drives investment decisions in health research today
(left side) [13,16–18].
doi:10.1371/journal.pmed.1001099.g001
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Research questions from all four broad research domains
(epidemiological research; health systems and policy research;
research to improve the existing interventions; and research to
develop new interventions) feature in the top 10% research
questions. When the 30 questions with highest overall scores are
considered (see Table S4), there is a predominance of research
questions from the domain of ‘‘epidemiological research’’ (12/30)
and health systems and policy research (8/30), while a smaller
number came from the domain of ‘‘research to improve the existing
interventions’’ (6/30) and ‘‘research to develop new interventions’’
(4/30). These results reflect the context of the exercise, i.e.
expectation of short to medium term impact, within 5–10 years.
This short time frame benefited epidemiological questions to assess
and confirm the value of existing and available cost-effective
interventions; health systems and policy research to identify key
obstacles to delivery of those interventions on a larger scale; and
optimising the use of those interventions (alone or in combination)
in different contexts. The highest ranked questions address issues
related to improving current case management and immunisation
interventions, including systems-based approaches. The highest
ranked issue is the study of barriers to care-seeking, an issue that is
rarely given high funding priority by international agencies.
Research questions seeking to develop new interventions had
only four representatives among the 30 highest ranked questions.
This is not surprising given the short specified time frame (i.e., 5–
10 years) by when it is really difficult to envisage new interventions
that could have substantial impact. The four ideas that were
strongly encouraged by the experts were development of: (i) low-
cost conjugate vaccines for pneumococcus; (ii) low-cost cross-
protective common protein vaccines for pneumococcus; (iii)
combination vaccine against common bacterial pathogens of
acute lower respiratory infections (ALRIs); and (iv) a new
approach to culture-appropriate health education on health-
seeking behaviour change. Among the bottom ranked 30 research
options, the majority proposed development of entirely new
interventions (20/30). In addition, six from the domain of
‘‘epidemiological research’’, and four from the domain of
‘‘improvement of existing interventions’’ were given low priority.
In the large majority of cases, the main reason for this was
minimal, or entirely non-existent, optimism towards their possible
impact on reduction of pneumonia within the context defined
above (i.e., by 2015). This was coupled with concerns over
effectiveness and deliverability of many of the proposed new
interventions, such as anti-inflammatory agents, antioxidants, or
other ideas, leading from fundamental molecular research of
uncertain answerability and effectiveness that seeks to identify
novel disease mechanisms and approaches to treatment. Another
common concern was that they would be the least likely to
improve equity, at least by the year 2015. For example, new
interventions are very likely to be initially available only to those
who can afford them.
Good discrimination between the levels of agreement among
the scorers on the priority of the 158 questions was achieved by
calculating AEA (Table 1; Table S4). The scores ranged from
46.7% to 76.3%, indicating the proportion of scorers that gave the
most common answer to an average question they were asked in
relation to a specific research investment option. AEA values are
also presented for the top 10% of research questions in Table 1.
Generally, the questions over which the greatest level of overall
agreement was observed among the experts were those that also
achieved very high overall research priority scores. The greatest
points of controversy were the research questions related to
development of entirely new interventions or some controversial
topics (e.g. antiviral drugs, exposure to cold air, the role of air
pollutants or combustion of biomass fuels, transdermal delivery of
antibiotics, or genetically modified crops for improved nutrition).
The scores given to all 158 research questions from individual
experts and their level of agreement for each research question are
presented in Table S5. The full list of technical experts who were
invited to participate, their expertise, and reasons for non-
participation from those who declined are presented in Table S6.
It is difficult to suimultaneously discuss strengths and weaknesses of
many proposed research questions that were ranked in the middle of
the list. Generally, these comprised a very broad mix of ideas of
possible novel interventions and diagnostic tests of uncertain
answerability and effectiveness; health policy and systems research
ideas with a very limited potential impact on overall mortality
reduction; support for new ideas that may not be affordable,
sustainable, or improve equity; and improvements to existing
interventions of uncertain deliverability and improved effect on
mortality. Table S4 offers many examples of such research proposals.
The results of this exercise, which involved a substantial number
of researchers active in studying the problem of childhood
pneumonia, exposed how entirely different research questions
can be considered research priorities depending on the criterion
used. Box 2 shows the three highest scoring research questions
within each of the five priority-setting criteria used. The research
that would be most answerable is related to determining risk factors
for severe pneumonia and referring sick children to a hospital.
This question was also among those most likely to be effective, and
carrying the greatest potential for disease burden reduction. Other
highly answerable questions were improving the definition of an
episode in a community and quantifying the problem of antibiotic
resistance. The ideas that were considered most likely to be effective
were studies to assess effectiveness of new conjugate pneumococcal
vaccines in different contexts and studying health systems capacity
to provide oxygen. The questions that would contribute to improved
outreach and delivery were those studying factors that affect
implementing and sustaining WHO’s acute respiratory infections
management strategy, studying the main barriers to increase
coverage by available vaccines, and assessing the effectiveness of
existing WHO treatment algorithms and guidelines. The greatest
potential for disease burden reduction was assigned to research studying
the main barriers to health care seeking and access, and the
development of combo-vaccines against common bacterial
pathogens. Research that would contribute mostly to improving
equity was a study of expanded diagnosis, referral, and antibiotic
treatment in a safe and effective way through community health
workers’ training, and evaluating culture-appropriate health
education and public health messages on health-seeking behaviour
change and hospitalisation.
Another sub-analysis that was allowed by the CHNRI process
was evaluating the research ideas related to increased oxygen
provision, which has often been a point of disagreement between
donors, researchers, and implementors. Table 2 suggests that
health systems research to improve availability of oxygen in health
facilities and on the (cost) effectiveness of pulse oximeter
technology should be given high investment priority within the
short-term context; research on improving oxygen concentrator
and other related technology be given medium priority; and
research to define thresholds and improve user acceptability be
given low priority. The exercise also illustrates the potential of this
simple structured scoring system to give clear prioritisation among
research options within a narrow research field and to give
guidance on strengths and weaknesses of individual research
questions to research policy-makers; in doing so, it limits individual
biases by drawing together a larger number of experts from
different backgrounds.
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Discussion
The highest ranked questions in our priority-setting exercise
address issues related to improving current case management and
immunisation interventions, including systems-base approaches.
This is not surprising, given that the context of the exercise was
defined with a very short time frame (5–10 years), to which
political commitment has been made through the support for the
idea of MDGs. It is of interest that the highest ranked issue is
the study of barriers to care-seeking, an issue that is rarely given
high funding priority by international agencies. The process
clearly showed how different research ideas can be seen as
priorities based on different criteria, but also how some research
questions satisfy most criteria and should represent apparent
research priorities.
In this paper, we were primarily interested in research priori-
ties that have a potential to reduce mortality from childhood
pneumonia globally, thus contributing to achievement of MDG4.
According to the most recent estimates, more than 99% of all
pneumonia deaths occur in low- and middle-income countries.
Because of this, addressing pneumonia deaths in wealthy countries by
health research would not carry any potential to contribute to the
main aim of our paper, and this is why the research on pneumonia in
the high-income context hasn’t been discussed. Furthermore, it takes
a considerable amount of time to translate the outcomes of health
research into interventions that, when rolled out, would indeed
achieve measurable impact on the burden of any disease at the global
level within a short time frame. This is why the proposed research
agenda presented in Table 1 should merely be regarded as
investments to accelerate progress toward the MDGs and beyond.
Box 2. The Three Highest Scoring Research Questions within Each of the Five Priority-Setting Criteria
(CHNRI Scores Can Range from 0 to 100)
ANSWERABILITY
1. Identify the key risk factors predisposing to the development of severe pneumonia and identify children who require
hospitalisation (99/100)
2. Measure and compare the burden of pneumonia using existing WHO definition and newer alternate definitions of ALRI/
clinical pneumonia that use X-ray or laboratory diagnostics and/or correct for diseases that mimic the presence of pneumonia
(96/100)
3. Measure the frequency of antibiotic resistance among cases of pneumonia caused by common respiratory bacterial
pathogens (96/100)
EFFECTIVENESS
1. Assess the effectiveness of new conjugate pneumococcal vaccines in reduction of childhood pneumonia morbidity and
mortality in different settings (96/100)
2. Identify the key risk factors predisposing to the development of severe pneumonia and identify children who require
hospitalisation (94/100)
3. Identify systems capacity to provide (and main barriers to increase) availability of oxygen in health facilities (94/100)
DELIVERABILITY
1. Identify factors that affect implementing and sustaining WHO’s acute respiratory infections management strategy (96/100)
2. Study the main barriers to increase coverage by available vaccines—measles and pertussis vaccines—in different contexts and
settings (94/100)
3. Assess the effectiveness of existing WHO treatment algorithms and guidelines on preventing pneumonia-related deaths,
unnecessary referrals, and unnecessary antibiotic use (93/100)
MAXIMUM POTENTIAL FOR MORTALITY REDUCTION
1. Identify the key risk factors predisposing to the development of severe pneumonia and identify children who require
hospitalisation (57/100)
2. Study the main barriers to health care seeking and health care assess for children with pneumonia in different contexts and
settings in developing countries (57/100)
3. Development of combo-vaccine against common bacterial pathogens of ALRI (57/100)
EQUITY
1. Study whether the coverage by antibiotic treatment can be greatly expanded in a safe and effective way if it was administered
by community health workers (97/100)
2. Can community volunteers be trained to adequately assess, recognise danger signs, refer, and treat acute respiratory
infections? (96/100)
3. Investigate efficacy of the impact of culture-appropriate health education and public health messages on health-seeking
behaviour change, hospitalisation, and mortality from childhood pneumonia (95/100)
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Towards Transparent and Systematic Priority Setting In
Global Health Research
The CHNRI methodology is a serious attempt to characterise
many issues in the highly complex process of research investment
priority setting; however, its validity is surely imperfect. For
example, some good ideas (‘‘research investment options’’) may
not have been included in the initial list of research options. Some
ideas might be included due to excessive media interest. The
conclusions represent the opinion of a limited group of involved
people. Those and other possible biases and limitations of the
method are described and discussed in greater detail in Table S1.
Nevertheless, the method has rapidly become the most frequently
applied tool to set research priorities at all levels, because it is very
cheap and practical, simple to apply via e-mail, transparent and
replicable, the output is intuitive and easily understood, and it has
been validated and improved through many exercises over the past
several years. We believe that it is important to use systematic and
transparent methods and processes, and large expert groups, to
keep exposing the strengths and weaknesses of different approach-
es in global health research. This should keep the focus of the
donors on the areas where funding is most needed, for as long as
the progress in reaching MDGs becomes truly satisfactory, and
prevent it from drifting into other areas for which there is a lot of
new advocacy, but not much evidence. We feel that the research
community has a responsibility to expose strengths and weaknesses
of the many competing ideas through transparent processes, and
thus to reassure both the donors and the end users of health
research investments that they should persist in supporting the
activities with true potential to make a difference and save lives.
Thus, the main goal of this paper was not to state the obvious, but
rather to expose strengths and weaknesses of many competing
existing and emerging research ideas. This should reassure the
broad global health community on the choices that could be
concluded reasonably quickly, and lead to interventions that
would be likely to demonstrate measurable impact within a shorter
time frame.
A Need for Coordinated, Evidence-Based, and Equitable
Research Investment Policies
The amount of funding available today for health research
globally is unprecedented and the research investment market has
been growing steadily over the past decade [23]. However, large
inequities exist between amounts invested in different conditions
that contribute to the global burden of disease. For example, while
research on diabetes type 2 receives more than US$100 per
DALY, research on pneumonia receives less than US$5 per DALY
[14,15,23]. Perhaps a more pressing issue is the way in which the
risk of investing in different health research domains is managed
today. Long-term strategic investments in basic research, which
are usually seen as highly uncertain, but also potentially highly
profitable, may be justified in cases of chronic diseases, because
those diseases can already be controlled by changes in diet and
lifestyle and do not cause imminent threat to life. However, the
situation with childhood diseases such as pneumonia and
diarrhoea is quite different. Those two diseases combined continue
to cause more child deaths each year worldwide than annual
deaths attributable to smoking in all ages, or twice as many annual
deaths as HIV/AIDS globally [13]. The persisting high mortality
from pneumonia in the presence of existing cost-effective
interventions and available resources to implement them repre-
sents a continuing scandal [13,24,25]. Given the consequences of
the disease in terms of persisting child mortality, the level of
Table 2. An example of oxygen-related questions.
Rank Proposed Research Question Answerable? Effective? Deliverable?
Burden
Reduction? Equitable? AEA (%)
RPS
(weighted)
11 Identify systems capacity to provide (and main barriers
to increase) availability of oxygen in health facilities
92 94 75 41 85 72.2 71.6
22 Determine effectiveness and cost-effectiveness of pulse
oximeter on the use of oxygen to treat pneumonia and
prevent deaths
89 81 75 35 77 67.4 66.0
58 Research to make oxygen concentrators further reduced
in size and to improve their reliability and length of life-
time without maintenance
77 76 80 29 79 63.0 62.0
64 Research of improving oxygen concentrator technology
to make it independent of electricity supply
89 70 75 27 80 65.2 61.9
70 Research to make technology related to oxygen
interventions more robust and easily deliverable in
both community settings and clinical practice
79 69 68 34 79 58.5 60.9
71 Optimise community-based oxygen therapy treatment
of lower respiratory infections and assess its effectiveness
79 80 59 29 86 62.2 60.8
97 Define the criteria (threshold) at which treatment with
oxygen improves survival
74 78 65 22 75 58.1 56.4
125 Identify strategies to improve acceptability of oxygen
usage for children by guardians
79 55 66 9 67 53.3 48.1
144 Investigate if inhaled pulmonary vasodilatators synergise
with oxygen and improve outcomes from very severe
pneumonia
77 38 39 10 61 56.3 40.1
Several of the experts implied an apparent discrepancy in the perceived importance of oxygen delivery between the donors for health research, technical experts, and
the implementers and programme leaders. The final ranks for the nine research questions related to oxygen research spread from 11th to 144th (among 158 suggested
ideas). The ratio between highest and lowest scores varied widely across criteria: answerability (1.24), effectiveness (2.47), deliverability (2.05), impact of disease burden
(4.56), impact on equity (1.39), and overall RPS (1.79). This example shows how a focus on addressing e.g., ‘‘oxygen research for pneumonia’’ would be too broad, and
that prioritisation should be made between more specific research ideas to be meaningful.
doi:10.1371/journal.pmed.1001099.t002
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urgency in dealing with this problem is very different than for
other chronic diseases that contribute heavily to DALYs [13]. We
believe that this should be reflected in global health research
policies and investment strategies.
Investment in global health research today would benefit from
consensus on the context, investment strategies, and coordination
to achieve significant reduction of the disease burden in the
foreseeable future—both among the investors, policy-makers, and
researchers. The present exercise was designed to assist them all in
making more informed choices on their investments in health
research on pneumonia by exposing the risks and potential
benefits associated with a broad spectrum of health research
options. The expected ‘‘profit’’ from investments is associated with
generating new knowledge that can be translated into develop-
ment of new (or improvement of existing) interventions that are
effective, deliverable, affordable, and can reduce the existing
burden of disease and disability in an equitable way. The risk is
associated with research that is not likely to satisfy some of those
criteria. Investors’ preference for high-risk investment in health
research is particularly questionable when it is occurring in a
context that requires urgent progress, such as childhood
pneumonia [13]. The focus on complex challenges of implemen-
tation (i.e., improving health systems, training health workers,
including poorly educated village health workers, improving drug
supply and delivery at the community level, etc.), which the
exercise highlighted, was reflected in many research questions
being ranked near the top of the list of overall priorities.
The implementation of the CHNRI methodology showed that,
within the context of MDG4, a better balance should be achieved
between specific domains of health research. Along with
continuing strategic long-term investments and new interventions,
which represent ‘‘high risk - high-profit’’, the CHNRI process
suggested that more attention should also be given to health policy
research, health systems research, operations research, and
research that addresses political, economic, social, cultural,
behavioural, and infrastructure issues surrounding the problem
of child mortality. These domains of health research are rarely
recognised as attractive by investors in health research because
their results are unlikely to grab the headlines, get considered by
journals with high impact factors, lead to patents or commercial
products. Yet, they can generate new knowledge that can be
exceptionally helpful in achieving real progress in mortality
reduction.
This was an exercise aimed mainly at identifying research
priorities to improve specific pneumonia prevention and manage-
ment. If a broader policy context was more inclusive, policy
research priorities to address underlying determinants (such as
environment, nutrition, women’s education, housing, social and
political context, etc.) would surely also emerge as very important.
A separate CHNRI exercise will investigate broader policies
addressing underlying determinants of child health and cross-
cutting issues that affect all major child diseases.
Evaluation of the Process and Further Steps
With the emergence of the CHNRI methodology, several group
leaders with the WHO spotted the opportunity to conduct an
inclusive and systematic exercise to define child health research
priorities globally that could help accelerate the progress towards
MDG4. They conducted the process from WHO headquarters in
Geneva, but included hundreds of external experts globally and
collected their opinions. This paper is one of the five papers that
resulted from this process, which has been seen as an example of a
helpful, systematic, and transparent priority-setting exercise [19–
21,24]. The members of the WHO CAH-based group were
eventually happy to conclude that the identified priorities were in
good agreement with the research that they already support at
present. They emphasised the evaluation of existing interventions
and the development and testing of new delivery approaches of
existing interventions. They also highlighted the value of research
on preventive measures, with research on new interventions being
downplayed within the short-term context. But in reality, even
these ‘‘shorter term’’ priorites (which can have more rapid impact
on mortality reduction) would still take 10–20 years to fully explore
in a developing country context, and past experiences have shown
that each of these top priorities would likely entail a global research
programme of a decade or more to see its impact fully realised.
Following the completion of the exercise, a large donor conference
called ‘‘Identifying priorities for Child Health Research to achieve
MDG4’’ was held at the WHO in Geneva on March 26–27, 2009.
More than 40 donor organisations were invited to choose and
support some of the identified priorities. A publication that will
summarise and discuss follow-up activities is in preparation.
Conclusions
The context for this exercise was set within MDG4, requiring an
urgent and rapid progress in mortality reduction from childhood
pneumonia, rather than identifying long-term strategic solutions of
the greatest potential. In a short-term context, the health policy
and systems research to improve access and coverage by the
existing interventions [25,26] and epidemiological research to
address the key gaps in knowledge [27] were highlighted as
research priorities. These questions are mainly targeted at better
understanding the barriers towards implementation, effectiveness,
and optimisation of use of available interventions and pro-
grammes. If progress towards the reduction of global pneumonia
mortality is to be improved by 2015, these are the research
questions that are most likely to be of greatest importance.
However, very few donors agencies recognise the importance of
these domains of health research to readily invest in those options
[14,15]. The core group of CHNRI experts made several serious
attempts to influence the key donors and point to this gap and
serious imbalance in health research investing between long-term,
strategic investments in basic research and support for instruments
of health research that could contribute to mortality reduction in
shorter term. This exercise, which involved much of the
pneumonia research community, is the best example to date
conducted at the global level.
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